GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Xoma Ltd. (XOMA) [hlAlert]

Rating:
Mkt Outperform
XOMA
down 98.17 %

Xoma Ltd. (XOMA) rated Mkt Outperform with price target $4 by Rodman & Renshaw

Posted on: Monday,  Mar 9, 2009  8:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Xoma Ltd. (NASDAQ: XOMA) on 03/09/2009. Previously Rodman & Renshaw rated Buy Xoma Ltd. (NASDAQ: XOMA)
on 11/27/2007., when the stock price was $45.45. Since then, Xoma Ltd. has lost 98.17% as of 11/27/2015's recent price of $0.83.
If you would have followed the previous Rodman & Renshaw's recommendation on XOMA, you would have lost 98.17% of your investment in 2922 days.

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA, a monoclonal antibody product marketed worldwide to treat moderate-to-severe plaque psoriasis, and LUCENTIS, a monoclonal antibody product marketed worldwide to treat neovascular age-related macular degeneration. The company has built a premier antibody discovery and development platform that includes access to seven of the leading commercially available antibody phage display libraries and XOMA's proprietary Human Engineering and bacterial cell expression technologies. More than forty five companies have signed BCE licenses. XOMA's development collaborators include Lexicon Genetics, Inc., Novartis, and Schering-Plough Corporation. With a fully integrated product development infrastructure, XOMA's product development capabilities extend from preclinical sciences to product launch.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/9/2009 8:25 AM Buy
None
7.97 60.00
as of 12/31/2009
1 Week down  -42.94 %
1 Month down  -48.26 %
3 Months down  -52.09 %
1 YTD down  -37.41 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/13/2008 10:25 AM Buy
None
31.50 75.00
11/27/2007 11:25 AM Buy
None
45.45 90.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy